Search results
PROMOTED
Start date:
Jan 21, 2026
Pacemaker implantation remains one of the most common complications after TAVI. In this webinar, chaired by Prof Rafal Dworakowski (Abbott APAC Medical Affairs Director, Singapore, SG) and Dr Simon Lam (Queen Mary Hospital, Hong Kong, HK), leading specialists will focus on the anatomy of the conduction system anatomy, highlight key pre-procedural planning considerations, and share proven…
View more
Complete Revascularisation in STEMI: Do We Really Buy It?
Added:
1 month ago
Review Article
Added:
2 months ago
OMI Confounded by LVH
Added:
6 months ago
Case Report
Complete Revascularisation Following Acute MI
Added:
1 year ago
Review Article
Added:
1 week ago
EuroPCR 2026 – Dr Brian Bergmark (Brigham and Women's Hospital, Boston, MA, US) joins us to discuss findings from the VESALIUS-CV trial, examining the effect of evolocumab in patients who have undergone coronary stenting but have no prior myocardial infarction or stroke.VESALIUS-CV is a double-blind, randomised, placebo-controlled, multicentre phase 3 trial enrolling 12,301 high-cardiovascular…
View more
Added:
2 months ago
ACC.26 – Dr Navin Kapur (Tufts Medicine, Boston, MA, US) joins us to discuss findings from the STEMI-Door To Unload (DTU) randomised clinical trial, examining whether primary left ventricular unloading with the Impella CP® device prior to reperfusion can reduce infarct size and heart failure-related outcomes in patients presenting with anterior ST-elevation myocardial infarction.This prospective,…
View more
Added:
1 year ago
Added:
2 months ago
Source:
Interventional Cardiology Review Journal
Long-term follow-up from the FAMOUS-NSTEMI trial suggests that a fractional flow reserve-guided strategy for managing patients with non-ST-segment elevation myocardial infarction (NSTEMI) does not reduce adverse cardiovascular outcomes compared to standard angiography-guided care.¹MethodologyFAMOUS-NSTEMI was a prospective, randomised, controlled trial that enrolled 350 patients with NSTEMI…
View more
Added:
2 months ago
Source:
Cardiac Failure Review
The optimal timing for complete revascularisation in patients with ST-segment elevation myocardial infarction (STEMI) and multi-vessel disease who also present with heart failure is a key clinical question. A pre-specified subgroup analysis of the OPTION-STEMI trial suggests that a staged approach may be preferable to immediate complete revascularisation in this high-risk patient group…
View more